Pulse Biosciences Reports Strong Long-Term Clinical Data for Thyroid Nodule Ablation System
PLSE sits 44% above its 52-week low of $12.56.
Summary
Pulse Biosciences reported positive long-term clinical data for its nPulse Vybrance system in treating benign thyroid nodules, showing durable volume reduction and high patient satisfaction.
Key Events · Product Development and Regulatory · PLSE
-
Durable Clinical Efficacy
The nPulse Vybrance system achieved an average 74% volume reduction of treated benign thyroid nodules, sustained over 15-22 months, with no regrowth.
-
High Patient Satisfaction & Safety
Patients reported 100% cosmetic satisfaction and 95% overall satisfaction, with no serious adverse events or intranodular fibrosis detected.
-
Expanded Market Potential
These positive long-term results for benign thyroid nodules demonstrate the potential for the company's nsPFA technology beyond its cardiac applications.
Analysis · PLSE · Industrial Applications And Services
Pulse Biosciences announced highly positive long-term follow-up data from its nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules. The study demonstrated durable 74% volume reduction, no regrowth, and high patient satisfaction (100% cosmetic, 95% overall) over 15-22 months, with no serious adverse events. This strong clinical evidence for a non-cardiac application of their nsPFA technology could significantly expand the company's market opportunities and provides a foundation for future development and commercialization efforts.
At the time of this filing, PLSE was trading at $18.12 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $12.56 to $26.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.